Skip to main content

Table 5 Association of HAART and other variables with dyslipidemia among HIV-infected patients

From: Highly active antiretroviral therapy and dyslipidemia in people living with HIV/AIDS in Fako Division, South West Region of Cameroon

Explanatory Variables TC ≥ 200 mg/dL AOR (95 % CI) LDL-c ≥ 130 mg/dL AOR (95 % CI) HDL-c < 40 mg/dL AOR (95 % CI) TG ≥ 150 mg/dL AOR (95 % CI) TC/HDL-c ≥ 5 AOR (95 % CI)
Antiretroviral therapy      
 HAART-naïve* 1.00 1.00 1.00 1.00 1.00
 HAART treated 6.24 (2.33-17.45) 5.28 (1.17-16.32) 1.07 (0.37-3.05) 0.86 (0.32-2.28) 2.51 (0.64-9.89)
p-value < 0.001 0.004 0.904 0.762 0.188
Gender      
 Male* 1.00 1.00 1.00 1.00 1.00
 Female 2.17 (0.99-4.74) 1.20 (0.55-2.65) 0.45 (0.19-1.07) 0.44 (0.19-1.01) 0.42 (0.16-1.09)
p-value 0.053 0.645 0.071 0.054 0.076
Age group      
  ≤ 40 years* 1.00 1.00 1.00 1.00 1.00
  > 40 years 1.11 (0.58-2.31) 0.91 (0.47-1.78) 0.80 (0.35-1.84) 1.22 (0.57-2.58) 1.02 (0.42-2.46)
 p-value 0.746 0.789 0.605 0.611 0.963
Body Mass Index      
 BMI < 25 kg/m2* 1.00 1.00 1.00 1.00 1.00
 BMI ≥ 25 kg/m2 0.98 (0.52-1.86) 1.07 (0.56-2.05) 0.88 (0.39-1.98) 3.25 (1.44-7.34) 2.19 (0.87-5.51)
p-value 0.962 0.845 0.757 0.005 0.097
HIV duration      
  < 42 months* 1.00 1.00 1.00 1.00 1.00
  ≥ 42 months 2.26 (1.16-4.42) 1.71 (0.85-3.45) 1.32 (0.53-3.29) 1.89 (0.81-4.41) 1.58 (0.60-4.13)
p-value 0.017 0.133 0.0.545 0.140 0.350
  1. TC-Total Cholesterol, LDL-c-Low-Density Lipoprotein Cholesterol, HDL-c-High-Density Lipoprotein Cholesterol, TG-Triglyceride; HAART-Highly Active Antiretroviral Therapy, AOR-Adjusted Odds Ratio, BMI-Body Mass Index; *-Reference category